Cargando…

Meta-analyses of treatment standards for pancreatic cancer

Pancreatic cancer is the most lethal common cancer with an estimated 5-year survival rate of 6–7% (across all stages). The only potential curative therapy is surgical resection in those with localized disease. Adjuvant (postoperative) therapy confers a survival advantage over postoperative observati...

Descripción completa

Detalles Bibliográficos
Autores principales:	GONG, JUN, TULI, RICHARD, SHINDE, ARVIND, HENDIFAR, ANDREW E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774516/ https://www.ncbi.nlm.nih.gov/pubmed/26998283 http://dx.doi.org/10.3892/mco.2015.716

Ejemplares similares

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
por: Gong, Jun, et al.
Publicado: (2018)

Pancreatic cancer ‘mismatch’ in Lynch syndrome
por: Hendifar, Andrew E, et al.
Publicado: (2019)

Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma
por: Reznik, Robert, et al.
Publicado: (2014)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

Advances in Pancreatic Ductal Adenocarcinoma Treatment
por: Anderson, Eric M., et al.
Publicado: (2021)

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
por: Gong, Jun, et al.
Publicado: (2018)

Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations
por: Gong, Jun, et al.
Publicado: (2019)

Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers
por: David, John M., et al.
Publicado: (2018)

Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients
por: Gresham, Gillian, et al.
Publicado: (2018)

Pancreatic cancer cachexia: a review of mechanisms and therapeutics
por: Tan, Carlyn R., et al.
Publicado: (2014)

Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma
por: Hendifar, Andrew, et al.
Publicado: (2016)

Combined morphologic and metabolic pipeline for Positron emission tomography/computed tomography based radiotherapy response evaluation in locally advanced pancreatic adenocarcinoma
por: Lao, Yi, et al.
Publicado: (2019)

Fecal elastase, an assay for exocrine pancreatic insufficiency, has clinical utility in patients with pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2020)

18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation
por: David, John M., et al.
Publicado: (2019)

Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas
por: Gong, Jun, et al.
Publicado: (2018)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

Palliative Radiation Therapy for Bone Metastases in Neuroendocrine Neoplasms
por: Guan, Michelle, et al.
Publicado: (2019)

Gut microbiome and pancreatic cancer cachexia: An evolving relationship
por: Hendifar, Andrew, et al.
Publicado: (2022)

Dietary Factors and Pancreatic Cancer Risk: An Umbrella Review of Meta-Analyses of Prospective Observational Studies
por: Qin, Xianpeng, et al.
Publicado: (2023)

Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol
por: Gong, Jun, et al.
Publicado: (2023)

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma
por: Ebia, Matthew I., et al.
Publicado: (2023)

Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma
por: Gong, Jun, et al.
Publicado: (2020)

Plasma Metabolomics Predicts Chemotherapy Response in Advanced Pancreatic Cancer
por: Muranaka, Hayato, et al.
Publicado: (2023)

Diets, Dietary Patterns, Single Foods and Pancreatic Cancer Risk: An Umbrella Review of Meta-Analyses
por: Gianfredi, Vincenza, et al.
Publicado: (2022)

Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations
por: Lee, Patrick C., et al.
Publicado: (2021)

A Rare Case of Primary Gastric HIV-Associated Peripheral T-Cell Lymphoma: Relapsed Disease Treated With Pemetrexed
por: Gong, Jun, et al.
Publicado: (2013)

Advanced pancreatic cancer: The standard of care and new opportunities
por: Mohammad, Amrallah A.
Publicado: (2018)

Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?
por: Fenocchio, Elisabetta, et al.
Publicado: (2019)

Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies
por: Hendifar, Andrew, et al.
Publicado: (2021)

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
por: Gong, Jun, et al.
Publicado: (2019)

Evaluation of the Reporting Standard Guidelines of Network Meta-Analyses in Physical Therapy: A Systematic Review
por: Cho, Sung-Hyoun, et al.
Publicado: (2022)

Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses
por: Yin, Jianyun, et al.
Publicado: (2022)

Tumor hyaluronan as a novel biomarker in non-small cell lung cancer: A retrospective study
por: Gong, Jun, et al.
Publicado: (2022)

Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses
por: Sultana, A, et al.
Publicado: (2008)

Efficacy and safety of traditional Chinese medicine for the treatment of pancreatic cancer: An overview of systematic reviews and meta-analyses
por: Wang, Jing, et al.
Publicado: (2022)

Cutting‐edge strategies for borderline resectable pancreatic cancer
por: Shinde, Rajesh S., et al.
Publicado: (2019)

Treatment of Pancreatic and Periampullary Cancers at a Community Hospital: Successful Application of Tertiary Care Treatment Standards
por: Moesinger, Robert C., et al.
Publicado: (2011)

Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers
por: Chuang, Jeremy, et al.
Publicado: (2022)

Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer
por: Walter, Thomas, et al.
Publicado: (2020)

Estimation in meta‐analyses of mean difference and standardized mean difference
por: Bakbergenuly, Ilyas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_13jtt5tvumv6krg9magm3aidd8